Skip to content
Tuesday, November 17, 2026 · Today’s edition, 6:30 a.m. ETTue, Nov 17 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in
XBISPDRINDEX

SPDR S&P Biotech ETF

$145.88-3.10% vs prior close
11417052-WK

Price through Nov 16, 2026 · Flows through Nov 13, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

XBI price

Source: Market tape, daily closes; price return, distributions not reinvested
Table
DateXBI close
Oct 16, 2026$144.32
Oct 19, 2026$147.86
Oct 20, 2026$153.24
Oct 21, 2026$152.78
Oct 22, 2026$151.64
Oct 23, 2026$149.54
Oct 26, 2026$150.47
Oct 27, 2026$154.84
Oct 28, 2026$157.51
Oct 29, 2026$157.79
Oct 30, 2026$155.98
Nov 2, 2026$152.05
Nov 3, 2026$154.97
Nov 4, 2026$159.10
Nov 5, 2026$148.40
Nov 6, 2026$152.21
Nov 9, 2026$156.90
Nov 10, 2026$155.06
Nov 11, 2026$156.31
Nov 12, 2026$151.20
Nov 13, 2026$150.55
Nov 16, 2026$145.88

Daily net flows, 1M

Net inflow over the range: +$108M

  • Inflow / above zero
  • Outflow / below zero
Oct 13Oct 15Oct 19Oct 21Oct 23Oct 27+$302.8MOct 29Nov 2Nov 4Nov 6Nov 10−$71.4MNov 13Oct 13Oct 16Oct 21Oct 26+$302.8MOct 29Nov 3Nov 6Nov 11−$71.4MNov 13Oct 13Oct 21+$302.8MOct 29Nov 6−$71.4MNov 13
Source: Daily creation and redemption records
Show as table
LabelValue ($)
Oct 13$96.7M
Oct 14$18.3M
Oct 15$67M
Oct 16−$66.2M
Oct 19−$264.4M
Oct 20$177.1M
Oct 21$272.7M
Oct 22−$38M
Oct 23−$44.9M
Oct 26−$222.1M
Oct 27−$148.5M
Oct 28$302.8M
Oct 29−$86.9M
Oct 30$285.9M
Nov 2−$138.9M
Nov 3−$146.7M
Nov 4$35.4M
Nov 5−$133.8M
Nov 6$30.1M
Nov 9−$89M
Nov 10$97.1M
Nov 11$3.9M
Nov 12$171.7M
Nov 13−$71.4M
The desk’s read

Money is leaving — −$8M in net outflows over the past month, while the price has returned +19.6% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$10.3Bassets under management
0.35%expense ratio · $35 per $10,000 a year
−$8Mnet flow, trailing month
9.2Mavg daily volume, 30 days
165holdings · US-domiciled
2006listed January 31, 2006 · beta 1.17
The book at a glance
MRNA-3.6%BIIB-0.7%AMGN-0.7%REGN-0.3%ABBV-0.2%UTHR-0.6%GILD-0.3%EXEL-2.8%TGTX-2.7%SYRE-4.5%ORKA-5.8%NBIX-1.2%VRTX-0.2%ALKS-1.1%BBIO-1.2%INCY-0.6%INSM+1.4%ROIV-2.3%KYMR-1.3%PTCT-4.0%BMRN+1.3%HALO-3.8%PRAX-5.4%CGON+14.0%KOD-9.4%NTRA-9.6%RYTM-6.6%ERAS-3.5%PTGX-4.7%KRYS-2.4%TWST-5.9%DNTH-2.5%PCVX-2.8%RVMD-3.1%MDGL-0.8%MIRM-2.6%TVTX-1.9%CRSP-4.4%COGT-3.9%CYTK-5.3%

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

Holdings
#HoldingWeightPriceDay52-wk
1MRNAMODERNA2.47%$215.27-3.6%
2BIIBBIOGEN1.80%$251.65-0.7%
3AMGNAMGEN1.79%$462.32-0.7%
4REGNREGENERON PHARMACEUTICALS1.78%$952.40-0.3%
5ABBVABBVIE1.76%$294.55-0.2%
6UTHRUNITED THERAPEUTICS1.75%$587.88-0.6%
7GILDGILEAD SCIENCES1.74%$167.58-0.3%
8EXELEXELIXIS1.78%$67.10-2.8%
9TGTXTG THERAPEUTICS1.77%$62.76-2.7%
10SYRESPYRE THERAPEUTICS INC1.80%$99.37-4.5%
11ORKAOruka Therapeutics1.73%$99.24-5.8%
12NBIXNEUROCRINE BIOSCIENCES1.62%$165.31-1.2%
13VRTXVERTEX PHARMACEUTICALS1.55%$537.79-0.2%
14ALKSALKERMES1.56%$46.53-1.1%
15BBIOBRIDGEBIO PHARMA1.55%$77.36-1.2%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.

Sign in to see all 165

Sector weights

  • Healthcare99.46%
  • Health Technology99.1%
  • Health Services0.86%
  • Financial Services0.54%
  • Other0.07%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
Healthcare99.46%
Health Technology99.1%
Health Services0.86%
Financial Services0.54%
Other0.07%

Country weights

  • United States96.69%
  • United Kingdom1.41%
  • Switzerland1.33%
  • Netherlands0.45%
  • Bermuda0.34%
  • Ireland0.08%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
United States96.69%
United Kingdom1.41%
Switzerland1.33%
Netherlands0.45%
Bermuda0.34%
Ireland0.08%
Performance
1 week-5.9%
1 month+1.1%
3 months-7.3%
6 months+11.6%
YTD+19.6%
1 year—
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week+$201M
1 month−$8M
3 months+$160M
YTD+$727M
1 year+$675M

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows

  • Inflow / above zero
  • Outflow / below zero
−$387.7MDec+$286.1MJan−$441.2MFeb−$590.6MMar+$627.7MApr−$231.2MMay+$922MJun−$366.3MJul+$765.8MAug−$689.2MSep+$685.4MOct−$241.6MNovDecJanFebMarAprMay+$922MJunJulAugSepOct−$241.6MNovDecFebApr+$922MJunAug−$241.6MNov
Source: Daily creation/redemption records, trailing twelve months
Show as table
LabelValue ($)
Dec−$387.7M
Jan$286.1M
Feb−$441.2M
Mar−$590.6M
Apr$627.7M
May−$231.2M
Jun$922M
Jul−$366.3M
Aug$765.8M
Sep−$689.2M
Oct$685.4M
Nov−$241.6M
The risk read
42%realized volatility, 30 days (annualized)
30%realized volatility, 1 year
-14.9%deepest fall from a peak, 1 year
-14.0%latest close versus that peak

The top holding is 2.5% of the book; the top ten carry 18%. Spread across 160+ names, it behaves like roughly 88 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
8Kcalls · latest snapshot
29Kputs · latest snapshot
3.69put/call ratio
10.2Mshares traded
Most-traded holdings, options premiumBullishBearish
MRNA MODERNA$30M$26M
SLS SELLAS LIFE SCIENCES GROUP$10M$13M
NTRA NATERA$20M$1M
SMMT SUMMIT THERAPEUTICS$5M$5M
CGON CG ONCOLOGY INC$3M$6M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against XBI

Due diligence cuts both ways. These funds sit on the same shelf and beat XBI on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW SPDR Portfolio Developed World ex-US ETF0.03%$41.6B+$917M-32bp on fee · 4× the assets · +$917M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.4B+$199M-32bp on fee · 2× the assets · +$199M in over the monthHead-to-head
IJH iShares Core S&P Mid-Cap ETF0.05%$123.7B+$109M-30bp on fee · 12× the assets · +$109M in over the monthHead-to-head
IDEV iShares Core MSCI International Developed Markets ETF0.04%$34B+$587M-31bp on fee · 3× the assets · +$587M in over the monthHead-to-head
IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF0.04%$23.7B+$422M-31bp on fee · 2× the assets · +$422M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.